Table 1.
Baseline characteristics of study participants
| Healthy volunteers | PAH patients | p value | |
|---|---|---|---|
| Number, n | 6 | 9 | |
| Age, years | 45.8 ± 8.9 | 41.8 ± 14.7 | 0.558 |
| Gender, n (male/female) | 4/2 | 1/8 | 0.089 |
| Height, cm | 163.2 ± 10.7 | 157.7 ± 5.8 | 0.288 |
| Body weight, kg | 60.4 ± 11.1 | 53.2 ± 6.4 | 0.234 |
| Body mass index, kg/m2 | 22.0 ± 2.5 | 21.4 ± 2.0 | 0.635 |
| Body surface area, m2 | 1.63 ± 0.20 | 1.52 ± 0.11 | 0.209 |
| IPAH/APAH, n | N/A | 5/4 | |
| PDE-5 inhibitors, n (%) | N/A | 8 (88.9) | |
| Endothelin receptor antagonists, n (%) | N/A | 8 (88.9) | |
| Prostanoids, n (%) | N/A | 5 (55.6) |
Data are expressed as n (%) or mean ± standard deviation
PAH pulmonary arterial hypertension, IPAH idiopathic pulmonary arterial hypertension, APAH associated pulmonary arterial hypertension, PDE-5 inhibitors phosphodiesterase 5 inhibitors, N/A not available